Technical Analysis for AUPH - Aurinia Pharmaceuticals Inc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Historical AUPH trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Overbought Stochastic | Strength | 4.01% | |
| Narrow Range Bar | Range Contraction | 3.94% | |
| NR7 | Range Contraction | 3.94% | |
| NR7-2 | Range Contraction | 3.94% | |
| Overbought Stochastic | Strength | 3.94% | |
| Narrow Range Bar | Range Contraction | 4.29% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Trending on StockTwits | 1 day ago | |
| Rose Above Upper Bollinger Band | 2 days ago | |
| Up 3% | 2 days ago | |
| Up 1 ATR | 2 days ago | |
| Up 2% | 2 days ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/11/2020
- Sector: Healthcare
- Industry: Biotechnology
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, is engaged in the development of a therapeutic drug to treat autoimmune diseases in Canada. The company's lead drug includes Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has a development and license agreement with 3SBio Inc. for the clinical development, registration, and commercialization of voclosporin in China; and licensing and collaboration agreement with Vifor Pharma for the treatment of lupus and various proteinuric nephrology indications. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.
Medicine Biopharmaceutical Life Sciences Drugs Autoimmune Diseases Peptides Immunosuppressants Lupus Lupus Nephritis Treatment Of Lupus
Medicine Biopharmaceutical Life Sciences Drugs Autoimmune Diseases Peptides Immunosuppressants Lupus Lupus Nephritis Treatment Of Lupus
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 21.93 |
| 52 Week Low | 3.52 |
| Average Volume | 1,672,667 |
| 200-Day Moving Average | 16.31 |
| 50-Day Moving Average | 14.36 |
| 20-Day Moving Average | 14.38 |
| 10-Day Moving Average | 14.59 |
| Average True Range | 0.57 |
| ADX | 11.93 |
| +DI | 29.82 |
| -DI | 18.18 |
| Chandelier Exit (Long, 3 ATRs ) | 13.85 |
| Chandelier Exit (Short, 3 ATRs ) | 14.80 |
| Upper Bollinger Band | 15.47 |
| Lower Bollinger Band | 13.29 |
| Percent B (%b) | 1.04 |
| BandWidth | 15.16 |
| MACD Line | 0.19 |
| MACD Signal Line | 0.04 |
| MACD Histogram | 0.1522 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 16.51 | ||||
| Resistance 3 (R3) | 16.41 | 15.98 | 16.35 | ||
| Resistance 2 (R2) | 15.98 | 15.74 | 16.03 | 16.30 | |
| Resistance 1 (R1) | 15.77 | 15.59 | 15.87 | 15.87 | 16.24 |
| Pivot Point | 15.34 | 15.34 | 15.40 | 15.40 | 15.34 |
| Support 1 (S1) | 15.13 | 15.10 | 15.24 | 15.23 | 14.86 |
| Support 2 (S2) | 14.70 | 14.95 | 14.76 | 14.80 | |
| Support 3 (S3) | 14.49 | 14.70 | 14.75 | ||
| Support 4 (S4) | 14.59 |
